drugset

drugset / Trial / NCT06727812

Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors

NCT06727812 ↗

Phase 1 Recruiting 206 enrolled Shandong Suncadia Medicine Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is an open, multicenter Phase I study to evaluate the safety and tolerability of HRS-6208 in patients with advanced solid tumors.

Timeline

Start: 2024-12-17
Primary completion: 2027-08
Completion: 2027-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS-6208	Unknown	—	—

Indications